ArticleCureus2025
Effectiveness and Safety of a Fixed-Dose Combination of Dapagliflozin and Vildagliptin in the Treatment of Type 2 Diabetes Mellitus: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The fixed-dose combination (FDC) of dapagliflozin 5 mg and vildagliptin 50 mg has been recently approved, but real-world data on its effectiveness and safety are limited. We aimed to evaluate the glycemic efficacy and safety of a combination therapy of dapagliflozin 5 mg and vildagliptin 50 mg in patients with type 2 diabetes mellitus (T2DM) over a three-month period. Materials and methods This single-center study retrospectively analyzed data from 49 T2DM patients treated with the FDC of dapagliflozin 5 mg and vildagliptin 50 mg, and complete baseline and three-month follow-up records were analyzed. The primary endpoint was the mean change in glycated hemoglobin (HbA1c). Secondary endpoints included fasting plasma glucose (FPG), postprandial plasma glucose (PPG), lipid profiles, and liver enzymes. Safety assessments included the frequency and nature of adverse events (AEs), such as hypoglycemia, genitourinary infections, gastrointestinal symptoms, and abnormalities in hepatic or renal function. Tolerability was defined as the absence of therapy discontinuation due to adverse effects. Results The study enrolled 101 patients with T2DM, of whom 49 patients completed the three-month follow-up (mean age: 55.31 ± 12.04 years) and were included in the analysis. The majority were obese based on Asia-Pacific/Indian body mass index (BMI) criteria (mean BMI: 27.25 ± 4.38 kg/m²). At baseline, the mean HbA1c was 8.87 ± 1.65%, with most patients having HbA1c levels above 8%. After three months of treatment, significant improvements in glycemic parameters were observed, with HbA1c reduced by 1.65 ± 1.23% (p < 0.001), FPG by 68.14 ± 54.31 mg/dL (p < 0.001), and PPG by 122.45 ± 83.08 mg/dL (p < 0.001). Lipid and liver enzyme profiles also showed significant improvement. Subgroup analyses showed consistent glycemic benefits across age, BMI, diabetes duration, and comorbidity categories. The FDC was well tolerated, with no serious AEs and only mild, self-limiting side effects. Conclusions This retrospective, single-center, short-term study suggests that dapagliflozin 5 mg and vildagliptin 50 mg may improve glycemic control in patients with T2DM over a three-month period; however, larger, long-term studies are required to confirm durability and safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.